authors
- O'Connor, Jeremy M
- Chiang, Anne C
- Joseph S. Ross, MD, MHS
- Abernethy, Amy P
- Cary Gross, MD
- Fessele, Kristen L
- Steiner, Jean
- Seidl-Rathkopf, Kathi
- Carson, Kenneth R
- Nussbaum, Nathan C
- Yin, Emily S
- Adelson, Kerin B
- Carolyn Presley
Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials.
- Overview
- Identity
- Additional Document Info
- View All
Overview
publication date
- January 1, 2018
published in
- JAMA oncology Journal
has subject area
- Aged
- Antibodies, Monoclonal, Humanized
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Clinical Trials as Topic
- Female
- Follow-Up Studies
- Humans
- Kidney Neoplasms
- Lung Neoplasms
- Male
- Middle Aged
- Nivolumab
- Practice Patterns, Physicians'
- Prognosis
- Programmed Cell Death 1 Receptor
- Retrospective Studies